Xiaojuan Mi

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

R. Lipton, A. Tockhorn-Heidenreich, J. Ford, 2022, Journal of medical economics.

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine

D. Buse, D. Ayer, J. Ford, 2023, Journal of Patient-Reported Outcomes.

Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States

R. Burge, Jerry Hall, W. Ye, 2023, Journal of medical economics.

Potential Savings in Caregiver Time and Societal Costs Associated with Slowing Disease Progression over 36 months in Patients with Early Alzheimer’s Disease: Findings from GERAS‐US

J. Johnston, W. Ye, E. Doty, 2022, Alzheimer's & Dementia.